The role of phospholipases in lipid modification and atherosclerosis

Cardiovascular Toxicology

Volumn 5, Issue 2, 2005, Pages 161-182

  Ghesquiere, Stijn A I ^a   Hofker, Marten H ^a   De Winther, Menno P J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Cytosolic; Group IIA; Group V; Group X; Mouse models; Phospholipase; Review

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE A4; LEUKOTRIENE B4; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHOLIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPASE; PHOSPHOLIPASE A2; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEOHEPARAN SULFATE; ROFECOXIB; SNAKE VENOM; SPHINGOMYELIN PHOSPHODIESTERASE; THROMBOXANE; UNINDEXED DRUG;

ALLERGIC REACTION; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL REGENERATION; DRUG EFFICACY; EPITHELIUM CELL; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; INTERNALIZATION; METABOLITE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; THROMBOCYTE AGGREGATION; VASOCONSTRICTION;

ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; HUMANS; ISOENZYMES; LIPID METABOLISM; LIPOPROTEINS, LDL; PHOSPHOLIPASES; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 23044484743     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:5:2:161     Document Type: Review

References (291)

1. Williams, K.J. and Tabas, I. (1995). The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15:551-561.
2. Glass, C.K. and Witztum, J.L. (2001). Atherosclerosis. the road ahead. Cell 104:503-516.
3. Libby, P., Ridker, P.M., and Maseri, A. (2002). Inflammation and atherosclerosis. Circulation 105:1135-1143.
4. Six, D.A. and Dennis, E.A. (2000). The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta 1488:1-19.
5. Sparrow, C.P., Parthasarathy, S., and Steinberg, D. (1988). Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J. Lipid Res. 29:745-753.
6. Sakai, M., Miyazaki, A., Hakamata, H., Sasaki, T., Yui, S., Yamazaki, M., et al. (1994). Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J. Biol. Chem. 269:31,430-31,435.
7. Needleman, P., Turk, J., Jakschik, B.A., Morrison, A.R., and Lefkowith, J.B. (1986). Arachidonic acid metabolism. Annu. Rev. Biochem. 55:69-102.
8. Smith, W.L., Garavito, R.M., and DeWitt, D.L. (1996). Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271:33,157-33,160.
9. Hanasaki, K. and Arita, H. (1999). Biological and pathological functions of phospholipase A(2) receptor. Arch. Biochem. Biophys. 372:215-223.
10. Hanasaki, K. (2004). Mammalian phospholipase A2: phospholipase A2 receptor. Biol. Pharm. Bull. 27:1165-1167.
11. Kanemasa, T., Hanasaki, K., and Arita, H. (1992). Migration of vascular smooth muscle cells by phospholipase A2 via specific binding sites. Biochim. Biophys. Acta 1125:210-214.
12. Houliston, R.A. and Wheeler-Jones, C.P. (2001). sPLA(2) cooperates with cPLA(2)alpha to regulate prostacyclin synthesis in human endothelial cells. Biochem. Biophys. Res. Commun. 287:881-887.
13. Dennis, E.A. (1997). The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22:1-2.
14. Dennis, E.A. (2000). Phospholipase A2 in eicosanoid generation. Am. J. Respir. Crit. Care Med. 161:S32-S35.
15. Scott, D.L., White, S.P., Otwinowski, Z., Yuan, W., Gelb, M.H., and Sigler, P.B. (1990). Interfacial catalysis: the mechanism of phospholipase A2. Science 250:1541-1546.
16. Scott, D.L. and Sigler, P.B. (1994). Structure and catalytic mechanism of secretory phospholipases A2. Adv. Protein Chem. 45:53-88.
17. Lee, B.I., Yoon, E.T., and Cho, W. (1996). Roles of surface hydrophobic residues in the interfacial catalysis of bovine pancreatic phospholipase A2. Biochemistry 35:4231-4240.
18. Han, S.K., Yoon, E.T., Scott, D.L., Sigler, P.B., and Cho, W. (1997). Structural aspects of interfacial adsorption. A crystallographic and site-directed mutagenesis study of the phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus. J. Biol. Chem. 272:3573-3582.
19. Snitko, Y., Koduri, R.S., Han, S.K., Othman, R., Baker, S.F., Molini, B.J., et al. (1997). Mapping the interfacial binding surface of human secretory group IIa phospholipase A2. Biochemistry 36:14,325-14,333.
20. Bittova, L., Sumandea, M., and Cho, W. (1999). A structure-function study of the C2 domain of cytosolic phospholipase A2. Identification of essential calcium ligands and hydrophobic membrane binding residues. J. Biol. Chem. 274:9665-9672.
21. Han, S.K., Kim, K.P., Koduri, R., Bittova, L., Munoz, N.M., Leff, A.R., et al. (1999). Roles of Trp31 in high membrane binding and proinflammatory activity of human group V phospholipase A2. J. Biol. Chem. 274:11,881-11,888.
22. Baker, S.F., Othman, R., and Wilton, D.C. (1998). Tryptophan-containing mutant of human (group IIa) secreted phospholipase A2 has a dramatically increased ability to hydrolyze phosphatidylcholine vesicles and cell membranes. Biochemistry 37:13,203-13,211.
23. Gelb, M.H., Cho, W., and Wilton, D.C. (1999). Interfacial binding of secreted phospholipases A(2): more than electrostatics and a major role for tryptophan. Curr. Opin. Struct. Biol. 9:428-432.
24. Kramer, R.M., Hession, C., Johansen, B., Hayes, G., McGray, P., Chow, E.P., et al. (1989). Structure and properties of a human non-pancreatic phospholipase A2. J. Biol. Chem. 264:5768-5775.
25. Minami, T., Tojo, H., Shinomura, Y., Matsuzawa, Y., and Okamoto, M. (1993). Purification and characterization of a phospholipase A2 from human ileal mucosa. Biochim. Biophys. Acta 1170:125-130.
26. Murakami, M., Nakatani, Y., Atsumi, G., Inoue, K., and Kudo, I. (1997). Regulatory functions of phospholipase A2. Crit. Rev. Immunol. 17:225-283.
27. Nevalainen, T.J., Gronroos, J.M., and Kallajoki, M. (1995). Expression of group II phospholipase A2 in the human gastrointestinal tract. Lab. Invest. 72:201-208.
28. Nevalainen, T.J., Meri, K.M., and Niemi, M. (1993). Synovial-type (group II) phospholipase A2 human seminal plasma. Andrologia 25:355-358.
29. Nevalainen, T.J., Marki, F., Kortesuo, P.T., Grutter, M.G., Di Marco, S., and Schmitz, A. (1993). Synovial type (group II) phospholipase A2 in cartilage. J. Rheumatol. 20:325-330.
30. Aitken, M.A., Thomas, T., Brennecke, S.P., Scott, K.F., and Rice, G.E. (1996). Localization of type II phospholipase A2 messenger RNA and immunoactivity in human placenta and fetal membranes. Placenta 17:423-429.
31. Rice, G.E., Wong, M.H., Farrugia, W., and Scott, K.F. (1998). Contribution of type II phospholipase A2 to in vitro phospholipase A2 enzymatic activity in human term placenta. J. Endocrinol. 157:25-31.
32. Kurihara, H., Nakano, T., Takasu, N., and Arita, H. (1991). Intracellular localization of group II phospholipase A2 in rat vascular smooth muscle cells and its possible relationship to eicosanoid formation. Biochim. Biophys. Acta 1082:285-292.
33. Murakami, M., Kudo, I., and Inoue, K. (1993). Molecular nature of phospholipases A2 involved in prostaglandin 12 synthesis in human umbilical vein endothelial cells. Possible participation of cytosolic and extracellular type II phospholipases A2. J. Biol. Chem. 268:839-844.
34. Rosenthal, M.D., Gordon, M.N., Buescher, E.S., Slusser, J.H., Harris, L.K., and Franson, R.C. (1995). Human neutrophils store type II 14-kDa phospholipase A2 in granules and secrete active enzyme in response to soluble stim-uli. Biochem. Biophys. Res. Commun. 208:650-656.
35. Barnette, M.S., Rush, J., Marshall, L.A., Foley, J.J., Schmidt, D.B., et al. (1994). Effects of scalaradial, a novel inhibitor of 14 kDa phospholipase A2, on human neutrophil function. Biochem. Pharmacol. 47:1661-1667.
36. Murakami, M., Kudo, I., Umeda, M., Matsuzawa, A., Takeda, M., Komada, M., et al. (1992). Detection of three distinct phospholipases A2 in cultured mast cells. J. Biochem. (Tokyo) 111:175-181.
37. Reddy, S.T. and Herschman, H.R. (1996). Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. J. Biol. Chem. 271:186-191.
38. Crowl, R.M., Stoller, T.J., Conroy, R.R., and Stoner, C.R. (1991). Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 266:2647-2651.
39. Barbour, S.E. and Dennis, E.A. (1993). Antisense inhibition of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P388D1 cells. J. Biol. Chem. 268:21,875-21,882.
40. Vial, D., Senorale-Pose, M., Havet, N., Molio, L., Vargaftig, B.B., and Touqui, L. (1995). Expression of the type-II phospholipase A2 in alveolar macrophages. Down-regulation by an inflammatory signal. J. Biol. Chem. 270:17,327-17,332.
41. Anthonsen, M.W., Stengel, D., Hourton, D., Ninio, E., and Johansen, B. (2000). Mildly oxidized LDL induces expression of group IIa secretory phospholipase A(2) in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 20:1276-1282.
42. Menschikowski, M., Kasper, M., Lattke, P., Schiering, A., Schiefer, S., Stockinger, H., et al. (1995). Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 118:173-181.
43. Elinder, L.S., Dumitrescu, A., Larsson, P., Hedin, U., Frostegard, J., and Claesson, H.E. (1997). Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler. Thromb. Vasc. Biol. 17:2257-2263.
44. Balboa, M.A., Balsinde, J., Winstead, M.V., Tischfield, J.A., and Dennis, E.A. (1996). Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J. Biol. Chem. 271:32,381-32,384.
45. Tischfield, J.A. (1997). A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J. Biol. Chem. 272:17,247-17,250.
46. Vadas, P. and Pruzanski, W. (1993). Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ. Shock 39:160-167.
47. Pruzanski, W., Keystone, E.C., Sternby, B., Bombardier, C., Snow, K.M., and Vadas, P. (1988). Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. J. Rheumatol. 15:1351-1355.
48. Rader, D.J. (2000). Inflammatory markers of coronary risk. N. Engl. J. Med. 343:1179-1182.
49. Murakami, M., Kambe, T., Shimbara, S., Yamamoto, S., Kuwata, H., and Kudo, I. (1999). Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway. J. Biol. Chem. 274:29,927-29,936.
50. Flood, C., Gustafsson, M., Pitas, R.E., Arnaboldi, L., Walzern, R.L., and Boren, J. (2004). Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler. Thromb. Vasc. Biol. 24:564-570.
51. Sartipy, P., Johansen, B., Gasvik, K., and Hurt-Camejo, E. (2000). Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions. Circ. Res. 86:707-714.
52. Kugiyama, K., Ota, Y., Sugiyama, S., Kawano, H., Doi, H., Soejima, H., et al. (2000). Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am. J. Cardiol. 86:718-722.
53. Couturier, C., Brouillet, A., Couriaud, C., Koumanov, K., Bereziat, G., and Andreani, M. (1999). Interleukin 1beta induces type II-secreted phospholipase A(2) gene in vascular smooth muscle cells by a nuclear factor kappaB and peroxisome proliferator-activated receptor-mediated process. J. Biol. Chem. 274:23,085-23,093.
54. Antonio, V., Brouillet, A., Janvier, B., Monne, C., Bereziat, G., Andreani, M., et al. (2002). Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: inter-play of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors. Biochem. J. 368:415-424.
55. Pfeilschifter, J., Schalkwijk, C., Briner, V.A., and van den Bosch, H. (1993). Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J. Clin. Invest. 92:2516-2523.
56. Grass, D.S., Felkner, R.H., Chiang, M.Y., Wallace, R.E., Nevalainen, T.J., Bennett, C.F., et al. (1996). Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J. Clin. Invest. 97:2233-2241.
57. Murakami, M., Koduri, R.S., Enomoto, A., Shimbara, S., Seki, M., Yoshihara, K., et al. (2001). Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms. J. Biol. Chem. 276:10,083-10,096.
58. Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., et al. (2000). Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275:32,783-32,792.
59. Bezzine, S., Koduri, R.S., Valentin, E., Murakami, M., Kudo, I., Ghomashchi, F., et al. (2000). Exogenously added human group X secreted phospholipase A(2) but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J. Biol. Chem. 275:3179-3191.
60. Enomoto, A., Murakami, M., Valentin, E., Lambeau, G., Gelb, M.H., et al. (2000). Redundant and segregated functions of granule-associated heparin-binding group II subfamily of secretory phospholipases A2 in the regulation of degranulation and prostaglandin D2 synthesis in mast cells. J. Immunol. 165:4007-4014.
61. Laine, V.J., Grass, D.S., and Nevalainen, T.J. (1999). Protection by group II phospholipase A2 against Staphylococcus aureus. J. Immunol. 162:7402-7408.
62. Qu, X.D. and Lehrer, R.I. (1998). Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect. Immun. 66:2791-2797.
63. Kennedy, B.P., Payette, P., Mudgett, J., Vadas, P., Pruzanski, W., Kwan, M., et al. (1995). A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270:22,378-22,385.
64. MacPhee, M., Chepenik, K.P., Liddell, R.A., Nelson, K.K., Siracusa, L.D., and Buchberg, A.M. (1995). The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81:957-966.
65. Gould, K.A. and Dove, W.F. (1997). Localized gene action controlling intestinal neoplasia in mice. Proc. Natl. Acad. Sci. USA 94:5848-5853.
66. Dove, W.F., Cormier, R.T., Gould, K.A., Halberg, R.B., Merritt, A.J., Newton, M.A., et al. (1998). The intestinal epithelium and its neoplasms: genetic, cellular and tissue interactions. Philos. Trans. R. Soc. Land. B Biol. Sci. 353:915-923.
67. Ivandic, B., Castellani, L.W., Wang, X.P., Qiao, J.H., Mehrabian, M., Navab, M., et al. (1999). Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 19:1284-1290.
68. Webb, N.R., Bostrom, M.A., Szilvassy, S.J., van der Westhuyzen, D.R., Daugherty, A., and de Beer, F.C. (2003). Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23:263-268.
69. Ghesquiere, S.A., Gijbels, M.J., Anthonsen, M., van Gorp, P.J., van der Made, I., Johansen, B., et al. (2005). Macrophage-specific overexpression of group IIa sPLA2 results in increased atherosclerotic lesion size and enhanced collagen deposition. J. Lipid Res. 46:201-210.
70. Sawada, H., Murakami, M., Enomoto, A., Shimbara, S., and Kudo, I. (1999). Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. Eur. J. Biochem. 263:826-835.
71. Murakami, M., Shimbara, S., Kambe, T., Kuwata, H., Winstead, M.V., Tischfield, J.A., et al. (1998). The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J. Biol. Chem. 273:14,411-14,423.
72. Murakami, M., Kambe, T., Shimbara, S., Higashino, K., Hanasaki, K., Arita, H., et al. (1999). Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem. 274:31,435-31,444.
73. Kim, Y.J., Kim, K.P., Rhee, H.J., Das, S., Rafter, J.D., Oh, Y.S., et al. (2002). Internalized group V secretory phospholipase A2 acts on the perinuclear membranes. J. Biol. Chem. 277:9358-9365.
74. Tischfield, J.A., Xia, Y.R., Shih, D.M., Klisak, I., Chen, J., Engle, S.J., et al. (1996). Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics 32:328-333.
75. Pan, Y.H., Yu, B.Z., Singer, A.C., Ghomashchi, F., Lambeau, G., Gelb, M.H., et al. (2002). Crystal structure of human group X secreted phospholipase A2. Electrostatically neutral interfacial surface targets zwitterionic mem-branes. J. Biol. Chem. 277:29,086-29,093.
76. Murakami, M., Masuda, S., Shimbara, S., Bezzine, S., Lazdunski, M., Lambeau, G., et al. (2003). Cellular arachidonate-releasing function of novel classes of secretory phospholipase A2s (groups III and XII). J. Biol. Chem. 278:10,657-10,667.
77. Gesquiere, L., Cho, W., and Subbaiah, P.V. (2002). Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry 41:4911-4920.
78. Gronroos, J.O., Laine, V.J., Janssen, M.J., Egmond, M.R., and Nevalainen, T.J. (2001). Bactericidal properties of group IIA and group V phospholipases A2. J. Immunol. 166:4029-4034.
79. Chen, J., Engle, S.J., Seilhamer, J.J., and Tischfield, J.A. (1994). Cloning, expression and partial characterization of a novel rat phospholipase A2. Biochim. Biophys. Acta 1215:115-120.
80. Chen, J., Engle, S.J., Seilhamer, J.J., and Tischfield, J.A. (1994). Cloning and recombinant expression of a novel human low molecular weight Ca(2+)-dependent phospholipase A2. J. Biol. Chem. 269:2365-2368.
81. Wooton-Kee, C.R., Boyanovsky, B.B., Nasser, M.S., de Villiers, W.J., and Webb, N.R. (2004). Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arteriosder. Thromb. Vasc. Biol. 24:762-767.
82. Evangelou, A.M. (1994). Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot. Essent. Fatty Acids 50:1-28.
83. Imaizumi, T.A., Stafforini, D.M., Yamada, Y., McIntyre, T.M., Prescott, S.M., and Zimmerman, G.A. (1995). Platelet-activating factor: a mediator for clinicians. J. Intern. Med. 238:5-20.
84. Farr, R.S., Cox, C.P., Wardlow, M.L., and Jorgensen, R. (1980). Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). Clin. Immunol. Immunopathol. 15:318-330.
85. Hakkinen, T., Luoma, J.S., Hiltunen, M.O., Macphee, C.H., Milliner, K.J., Patel, L., et al. (1999). Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 19:2909-2917.
86. Asano, K., Okamoto, S., Fukunaga, K., Shiomi, T., Mori, T., Iwata, M., et al. (1999). Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem. Biophys. Res. Commun. 261:511-514.
87. Tjoelker, L.W., Wilder, C., Eberhardt, C., Stafforini, D.M., Dietsch, G., Schimpf, B., et al. (1995). Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374:549-553.
88. Tjoelker, L.W., Eberhardt, C., Unger, J., Trong, H.L., Zimmerman, G.A., McIntyre, T.M., et al. (1995). Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J. Biol. Chem. 270: 25,481-25,487.
89. Stafforini, D.M., Prescott, S.M., and McIntyre, T.M. (1987). Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262:4223-4230.
90. Wardlow, M.L., Cox, C.P., Meng, K.E., Greene, D.E., and Farr, R.S. (1986). Substrate specificity and partial characterization of the PAF-acylhydrolase in human serum that rapidly inactivates platelet-activating factor. J. Immunol. 136:3441-3446.
91. Imaizumi, T. (1996). The fate of platelet-activating factor: PAF acetylhydrolases from plasma and tissues. In Lipobiology (Gross, R., ed), JAI Press, CT, pp. 141-162.
92. Noto, H., Hara, M., Karasawa, K., Iso, O.N., Satoh, H., Togo, M., et al. (2003). Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23:829-835.
93. Steinbrecher, U.P. and Pritchard, P.H. (1989). Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J. Lipid Res. 30:305-315.
94. Stremler, K.E., Stafforini, D.M., Prescott, S.M., and McIntyre, T.M. (1991). Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipidsas substrates. J. Biol. Chem. 266:11,095-11,103.
95. Stremler, K.E., Stafforini, D.M., Prescott, S.M., Zimmerman, G.A., and McIntyre, T.M. (1989). An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J. Biol. Chem. 264:5331-5334.
96. Min, J.H., Wilder, C., Aoki, J., Arai, H., Inoue, K., Paul, L., et al. (2001). Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. Biochemistry 40:4539-4549.
97. Liu, M. and Subbaiah, P.V. (1994). Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase. Proc. Natl. Acad. Sci. USA 91:6035-6039.
98. Tsoukatos, D.C., Liapikos, T.A., Tselepis, A.D., Chapman, M.J., and Ninio, E. (2001). Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein. Biochem. J. 357:457-464.
99. Tselepis, A.D., Dentan, C., Karabina, S.A., Chapman, M.J., and Ninio, E. (1995). PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vasc. Biol. 15:1764-1773.
100. Caslake, M.J., Packard, C.J., Suckling, K.E., Holmes, S.D., Chamberlain, P., and Macphee, C.H. (2000). Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150:413-419.
101. Tsaoussis, V. and Vakirtzi-Lemonias, C. (1994). The mouse plasma PAF acetylhydrolase: II. It consists of two enzymes both associated with the HDL. J. Lipid Mediators Cell Signalling 9:317-331.
102. Rodrigo, L., Mackness, B., Durrington, P.N., Hernandez, A., and Mackness, M.I. (2001). Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354:1-7.
103. Glomset, J.A. (1968). The plasma lecithins:cholesterol acyltransferase reaction. J. Lipid Res. 9:155-167.
104. Aron, L., Jones, S., and Fielding, C.J. (1978). Human plasma lecithin-cholesterol acyltransferase. Characterization of cofactor-dependent phospholipase activity. J. Biol. Chem. 253:7220-7226.
105. McCall, M.R., van den Berg, J.J., Kuypers, F.A., Tribble, D.L., Krauss, R.M., Knoff, L.J., et al. (1994). Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk. Arterioscler. Thromb. 14:248-253.
106. Subbaiah, P.V. and Liu, M. (1996). Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of transesterification of oxidized phospholipids. Biochim. Biophys. Acta 1301:115-126.
107. Chisolm, G.M. and Steinberg, D. (2000). The oxidative modification hypothesis of atherogenesis: an overview. Free Radic. Biol. Med. 28:1815-1826.
108. Quarck, R., De Geest, B., Stengel, D., Mertens, A., Lox, M., Theilmeier, G., et al. (2001). Adenovirus-mediated gene transfer of human platelet-activating factor-acetyl-hydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103:2495-2500.
109. Min, J.H., Jain, M.K., Wilder, C., Paul, L., Apitz-Castro, R., Aspleaf, D.C., et al. (1999). Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry 38:12,935-12,942.
110. MacPhee, C.H., Moores, K.E., Boyd, H.F., Dhanak, D., Ife, R.J., Leach, C.A., et al. (1999). Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338 (Pt. 2):479-487.
111. Packard, C.J., O'Reilly, D.S., Caslake, M.J., McMahon, A.D., Ford, I., Cooney, J., et al. (2000). Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343:1148-1155.
112. Tselepis, A.D. and John Chapman, M. (2002). Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 3:57-68.
113. Cupillard, L., Koumanov, K., Mattei, M.G., Lazdunski, M., and Lambeau, G. (1997). Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J. Biol. Chem. 272:15,745-15,752.
114. Hanasaki, K., Ono, T., Saiga, A., Morioka, Y., Ikeda, M., Kawamoto, K., et al. (1999). Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells. J. Biol. Chem. 274:34,203-34,211.
115. Morioka, Y., Saiga, A., Yokota, Y., Suzuki, N., Ikeda, M., Ono, T., et al. (2000). Mouse group X secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor. Arch. Biochem. Biophys. 381:31-42.
116. van Eijk, J.H., Verheij, H.M., Dijkman, R., and de Haas, G.H. (1983). Interaction of phospholipase A2 from Naja melanoleuca snake venom with monomeric substrate analogs. Activation of the enzyme by protein-protein or lipid-protein interactions? Eur. J. Biochem. 132:183-188.
117. Jain, M.K., Egmond, M.R., Verheij, H.M., Apitz-Castro, R., Dijkman, R., and De Haas, G.H. (1982). Interaction of phospholipase A2 and phospholipid bilayers. Biochim. Biophys. Acta 688:341-348.
118. Singer, A.G., Ghomashchi, F., Le Calvez, C., Bollinger, J., Bezzine, S., Rouault, M., et al. (2002). Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J. Biol. Chem. 277:48,535-48,549.
119. Hanasaki, K., Yamada, K., Yamamoto, S., Ishimoto, Y., Saiga, A., Ono, T., et al. (2002). Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 277:29,116-29,124.
120. Murakami, M. and Kudo, I. (2004). Secretory phospholipase A2. Biol. Pharm. Bull. 27:1158-1164.
121. Kim, K.P., Rafter, J.D., Bittova, L., Han, S.K., Snitko, Y., Munoz, N.M., et al. (2001). Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils. A potential role of heparan sulfate binding in PLA2 internalization and degradation. J. Biol. Chem. 276:11,126-11,134.
122. Saiga, A., Morioka, Y., Ono, T., Nakano, K., Ishimoto, Y., Arita, H., et al. (2001). Group X secretory phospholipase A(2) induces potent productions of various lipid mediators in mouse peritoneal macrophages. Biochim. Biophys. Acta 1530:67-76.
123. Morioka, Y., Ikeda, M., Saiga, A., Fujii, N., Ishimoto, Y., Arita, H., et al. (2000). Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE (2) formation during colon tumorigenesis. FEBS Lett 487:262-266.
124. Cupillard, L., Mulherkar, R., Gomez, N., Kadam, S., Valentin, E., Lazdunski, M., and Lambeau, G. (1999). Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor. J. Biol. Chem. 274:7043-7051.
125. Arita, H., Hanasaki, K., Nakano, T., Oka, S., Teraoka, H., and Matsumoto, K. (1991). Novel proliferative effect of phospholipase A2 in Swiss 3T3 cells via specific binding site. J. Biol. Chem. 266:19,139-19,141.
126. Hanasaki, K. and Arita, H. (2002). Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2. Prostaglandins Other Lipid Mediat. 68-69:71-82.
127. Hanasaki, K., Yokota, Y., Ishizaki, J., Itoh, T., and Arita, H. (1997). Resistance to endotoxic shock in phospholipase A2 receptor-deficient mice. J. Biol. Chem. 272: 32,792-32,797.
128. Yokota, Y., Higashino, K., Nakano, K., Arita, H., and Hanasaki, K. (2000). Identification of group X secretory phospholipase A(2) as a natural ligand for mouse phospholipase A(2) receptor. FEBS Lett. 478:187-191.
129. Yokota, Y., Notoya, M., Higashino, K., Ishimoto, Y., Nakano, K., Arita, H., et al. (2001). Clearance of group X secretory phospholipase A(2) via mouse phospholipase A(2) receptor. FEBS Lett. 509:250-254.
130. Kini, R.M. and Evans, H.J. (1989). A model to explain the pharmacological effects of snake venom phospholipases A2. Toxicon 27:613-635.
131. Higashino Ki, K., Yokota, Y., Ono, T., Kamitani, S., Arita, H., and Hanasaki, K. (2002). Identification of a soluble form phospholipase A2 receptor as a circulating endogenous inhibitor for secretory phospholipase A2. J. Biol. Chem. 277:13,583-13,588.
132. Ancian, P., Lambeau, G., Mattei, M.G., and Lazdunski, M. (1995). The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J. Biol. Chem. 270:8963-8970.
133. Balsinde, J., Balboa, M.A., and Dennis, E.A. (1998). Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc. Natl. Acad. Sci. USA 95:7951-7956.
134. Balsinde, J. and Dennis, E.A. (1996). Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. J. Biol. Chem. 271:6758-6765.
135. Evans, J.H., Spencer, D.M., Zweifach, A., and Leslie, C.C. (2001). Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes. J. Biol. Chem. 276:30,150-30,160.
136. Hirabayashi, T., Kume, K., Hirose, K., Yokomizo, T., Iino, M., Itoh, H., et al. (1999). Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A2. J. Biol. Chem. 274:5163-5169.
137. Lin, L.L., Wartmann, M., Lin, A.Y., Knopf, J.L., Seth, A., and Davis, R.J. (1993). cPLA2 is phosphorylated and activated by MAP kinase. Cell 72:269-278.
138. Hefner, Y., Borsch-Haubold, A.G., Murakami, M., Wilde, J.I., Pasquet, S., Schieltz, D., et al. (2000). Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J. Biol. Chem. 275:37,542-37,551.
139. Wijkander, J., O'Flaherty, J.T., Nixon, A.B., and Wykle, R.L. (1995). 5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils. J. Biol. Chem. 270:26,543-26,549.
140. Uozumi, N., Kume, K., Nagase, T., Nakatani, N., Ishii, S., Tashiro, F., et al. (1997). Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 390:618-622.
141. Takaku, K., Sonoshita, M., Sasaki, N., Uozumi, N., Doi, Y., Shimizu, T., et al. (2000). Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem. 275:34,013-34,016.
142. Smith, W.L. and Marnett, L.J. (1991). Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta 1083:1-17.
143. Dubois, R.N., Abramson, S.B., Crofford, L., Gupta, R.A., Simon, L.S., Van De Putte, L.B., et al. (1998). Cyclooxygenase in biology and disease. FASEB J. 12:1063-1073.
144. Samuelsson, B. (1983). From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Biosci. Rep. 3:791-813.
145. Vane, J.R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231:232-235.
146. Vila, L. (2004). Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med. Res. Rev. 24:399-424.
147. Willoughby, D.A., Moore, A.R., and Colville-Nash, P.R. (2000). COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355:646-648.
148. Botting, R.M. (2000). Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis. 31 (Suppl. 5):S202-210.
149. Kim, B.H., Kang, K.S., and Lee, Y.S. (2004). Effect of retinoids on LPS-induced COX-2 expression and COX-2 associated PGE(2) release from mouse peritoneal macrophages and TNF-alpha release from rat peripheral blood mononuclear cells. Toxicol. Lett. 150:191-201.
150. Guastadisegni, C., Nicolini, A., Balduzzi, M., Ajmone-Cat, M.A., and
151. Mitchell, J.A., Belvisi, M.G., Akarasereenont, P., Robbins, R.A., Kwon, O.J., Croxtall, J., et al. (1994). Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br. J. Pharmacol. 113:1008-1014.
152. Chandrasekharan, N.V., Dai, H., Roos, K.L., Evanson, N.K., Tomsik, J., Elton, T.S., et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99:13,926-13,931.
153. Schwab, J.M., Schluesener, H.J., and Laufer, S. (2003). COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 361:981-982.
154. Simon, L.S. (1999). Role and regulation of cyclooxygenase-2 during inflammation. Am. J. Med. 106:37S-42S.
155. Khuri, F.R., Wu, H., Lee, J.J., Kemp, B.L., Lotan, R., Lippman, S.M., et al. (2001). Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7:861-867.
156. Meade, E.A., McIntyre, T.M., Zimmerman, G.A., and Prescott, S.M. (1999). Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem. 274:8328-8334.
157. Baker, C.S., Hall, R.J., Evans, T.J., Pomerance, A., Maclouf, J., Creminon, C., et al. (1999). Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol. 19:646-655.
158. Schonbeck, U., Sukhova, G.K., Graber, P., Coulter, S., and Libby, P. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155:1281-1291.
159. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D.J. (2000). Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102:840-845.
160. Cipollone, F., Prontera, C., Pini, B., Marini, M., Fazia, M., De Cesare, D., et al. (2001). Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104:921-927.
161. McAdam, B.F., Catella-Lawson, F., Mardini, I.A., Kapoor, S., Lawson, J.A., and FitzGerald, G.A. (1999). Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 96:272-277.
162. Catella-Lawson, F., McAdam, B., Morrison, B.W., Kapoor, S., Kujubu, D., Antes, L., et al. (1999). Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289:735-741.
163. Siegle, I., Klein, T., Zou, M.H., Fritz, P., and Komhoff, M. (2000). Distribution and cellular localization of prostacyclin synthase in human brain. J. Histochem. Cytochem. 48:631-641.
164. Liou, J.Y., Shyue, S.K., Tsai, M.J., Chung, C.L., Chu, K.Y., and Wu, K.K. (2000). Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J. Biol. Chem. 275:15,314-15,320.
165. Korita, D., Sagawa, N., Itoh, H., Yura, S., Yoshida, M., Kakui, K., et al. (2002). Cyclic mechanical stretch augments prostacyclin production in cultured human uterine myometrial cells from pregnant women: possible involvement of up-regulation of prostacyclin synthase expression. J. Clin. Endocrinol. Metab. 87:5209-5219.
166. Miyata, A., Hara, S., Yokoyama, C., Inoue, H., Ullrich, V., and Tanabe, T. (1994). Molecular cloning and expression of human prostacyclin synthase. Biochem. Biophys. Res. Commun. 200:1728-1734.
167. Fleisher-Berkovich, S. and Danon, A. (1999). IL-1alpha but not IL-1 beta-induced prostaglandin synthesis is inhibited by corticotropin-releasing factor. Cytokine 11:239-243.
168. Chevalier, D., Cauffiez, C., Bernard, C., Lo-Guidice, J.M., Allorge, D., Fazio, F., et al. (2001). Characterization of new mutations in the coding sequence and 5′-untranslated region of the human prostacylcin synthase gene (CYP8A1). Hum. Genet. 108:148-155.
169. Moncada, S., Gryglewski, R., Bunting, S., and Vane, J.R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-665.
170. Numaguchi, Y., Naruse, K., Harada, M., Osanai, H., Mokuno, S., Murase, K., et al. (1999). Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler. Thromb. Vasc. Biol. 19:727-733.
171. Mukherjee, D., Nissen, S.E., and Topol, E.J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959.
172. Blumenstein, M., Keelan, J.A., and Mitchell, M.D. (2001). Hypoxia attenuates PGE(2)but increases prostacyclin and thromboxane production in human term villous trophoblast. Placenta 22:519-525.
173. Moncada, S. and Vane, J.R. (1979). Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N. Engl. J. Med. 300:1142-1147.
174. Vane, J.R. and Botting, R.M. (1995). Pharmacodynamic profile of prostacyclin. Am. J. Cardiol. 75:3A-10A.
175. Yokoyama, C., Miyata, A., Ihara, H., Ullrich, V., and Tanabe, T. (1991). Molecular cloning of human platelet thromboxane A synthase. Biochem. Biophys. Res. Commun. 178:1479-1484.
176. Ohashi, K., Ruan, K.H., Kulmacz, R.J., Wu, K.K., and Wang, L.H. (1992). Primary structure of human thromboxane synthase determined from the cDNA sequence. J. Biol. Chem. 267:789-793.
177. Shen, R.F. and Tai, H.H. (1998). Thromboxanes: synthase and receptors. J. Biomed. Sci. 5:153-172.
178. Dusting, G.J., Moncada, S., and Vane, J.R. (1977). Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins 13:3-15.
179. Hamberg, M., Svensson, J., and Samuelsson, B. (1975). Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72:2994-2998.
180. Hornby, E.J. and Skidmore, I.E. (1982). Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production. Biochem. Pharmacol. 31:1158-1160.
181. Yamada, M., Numaguchi, Y., Okumura, K., Harada, M., Naruse, K., Matsui, H., et al. (2002). Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries. Arterioscler. Thromb. Vasc. Biol. 22:256-262.
182. Cheng, Y., Austin, S.C., Rocca, B., Koller, B.H., Coffman, T.M., Grosser, T., et al. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541.
183. Vane, J.R. and Botting, R.M. (1998). Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 47 (Suppl. 2):S78-87.
184. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., et al. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255.
185. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl J. Med. 343:1520-1528.
186. Konstam, M.A., Weir, M.R., Reicin, A., Shapiro, D., Sperling, R.S., Barr, E., et al. (2001). Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104:2280-2288.
187. Graham, D.J. (2004). Risk of acute infaction and sudden cardiac death in patients treated with COX-2 selective and non-selective NSAIDs. In Inflammopharmacology. Office of Drug Safety.
188. FitzGerald, G.A. (2003). COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2:879-890.
189. Juni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P.A., and Egger, M. (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021-2029.
190. Solomon, D.H., Glynn, R.J., Levin, R., and Avorn, J. (2002). Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. 162:1099-1104.
191. Watson, D.J., Rhodes, T., Cai, B., and Guess, H.A. (2002). Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 162:1105-1110.
192. Rahme, E., Pilote, L., and LeLorier, J. (2002). Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. 162:1111-1115.
193. Bea, F., Blessing, E., Bennett, B.J., Kuo, C.C., Campbell, L.A., Kreuzer, J., et al. (2003). Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc. Res. 60:198-204.
194. Belton, O.A., Duffy, A., Toomey, S., and Fitzgerald, D.J. (2003). Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108:3017-3023.
195. Qi, Z., Hao, C.M., Langenbach, R.I., Breyer, R.M., Redha, R., Morrow, J.D., et al. (2002). Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110:61-69.
196. Morham, S.G., Langenbach, R., Loftin, C.D., Tiano, H.F., Vouloumanos, N., Jennette, J.C., et al. (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482.
197. Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., and Kudo, I. (2000). Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 275:32,775-32,782.
198. Jakobsson, P.J., Thoren, S., Morgenstern, R., and Samuelsson, B. (1999). Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 96:7220-7225.
199. Forsberg, L., Leeb, L., Thoren, S., Morgenstern, R., and Jakobsson, P. (2000). Human glutathione dependent prostaglandin E synthase: gene structure and regulation. FEBS Lett. 471:78-82.
200. Stichtenoth, D.O., Thoren, S., Bian, H., Peters-Golden, M., Jakobsson, P.J., and Crofford, L.J. (2001). Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J. Immunol. 167:469-474.
201. Naraba, H., Yokoyama, C., Tago, N., Murakami, M., Kudo, I., Fueki, M., et al. (2002). Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J. Biol. Chem. 277:28,601-28,608.
202. Kojima, F., Naraba, H., Sasaki, Y., Okamoto, R., Koshino, T., and Kawai, S. (2002). Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J. Rheumatol. 29:1836-1842.
203. Soler, M., Camacho, M., Escudero, J.R., Iniguez, M.A., and Vila, L. (2000). Human vascular smooth muscle cells but not endothelial cells express prostaglandin E synthase. Circ. Res. 87:504-507.
204. Matsumoto, H., Naraba, H., Murakami, M., Kudo, I., Yamaki, K., Ueno, A., and Oh-ishi, S. (1997). Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem. Biophys. Res. Commun. 230:110-114.
205. Coleman, R.A., Smith, W.L., and Narumiya, S. (1994). International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:205-229.
206. Libby, P., Warner, S.J., and Friedman, G.B. (1988). Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J. Clin. Invest. 81:487-498.
207. Corcoran, M.L., Stetler-Stevenson, W.G., DeWitt, D.L., and Wahl, L.M. (1994). Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes. Arch. Biochem. Biophys. 310:481-488.
208. Cipollone, F., Fazia, M., Iezzi, A., Ciabattoni, G., Pini, B., Cuccurullo, C., et al. (2004). Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 24:1259-1265.
209. Callejas, N.A., Casado, M., Diaz-Guerra, M.J., Bosca, L., and Martin-Sanz, P. (2001). Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33:860-867.
210. Shankavaram, U.T., Lai, W.C., Netzel-Arnett, S., Mangan, P.R., Ardans, J.A., Caterina, N., et al. (2001). Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J. Biol. Chem. 276:19027-19032.
211. Wesley, R.B. 2nd, Meng, X., Godin, D., and Galis, Z.S. (1998). Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler. Thromb. Vasc. Biol 18:432-440.
212. Hinson, R.M., Williams, J.A., and Shacter, E. (1996). Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. USA 93:4885-4890.
213. Takayama, K., Garcia-Cardena, G., Sukhova, G.K., Comander, J., Gimbrone, M.A. Jr., and Libby, P. (2002). Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J. Biol. Chem. 277:44,147-44,154.
214. Haugen, G. and Helland, I. (2001). Influence of preeclampsia or maternal intake of omega-3 fatty acids on the vasoactive effect of prostaglandin F-two-alpha in human umbilical arteries. Gynecol. Obstet. Invest. 52:75-81.
215. Palea, S., Toson, G., Pietra, C., Trist, D.G., Artibani, W., Romano, O., et al. (1998). Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder. Br. J. Pharmacol. 124:865-872.
216. Peri, K.G., Quiniou, C., Hou, X., Abran, D., Varma, D.R., Lubell, W.D., et al. (2002). THG113: a novel selective FP antagonist that delays preterm labor. Semin. Perinatol. 26:389-397.
217. Stier, C.T. Jr., Roberts, L.J. 2nd, and Wong, P.Y. (1987). Renal response to 9 alpha, 11 beta-prostaglandin F2 in the rat. J. Pharmacol. Exp. Ther. 243:487-491.
218. Honda, K., Arima, M., Cheng, G., Taki, S., Hirata, H., Eda, F., et al. (2003). Prostaglandin D2 reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine. J. Exp. Med. 198:533-543.
219. Arimura, A., Yasui, K., Kishino, J., Asanuma, F., Hasegawa, H., Kakudo, S., et al. (2001). Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J. Pharmacol. Exp. Ther. 298:411-419.
220. Fujitani, Y., Kanaoka, Y., Aritake, K., Uodome, N., Okazaki-Hatake, K., and Urade, Y. (2002). Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J. Immunol. 168:443-449.
221. Minami, T., Okuda-Ashitaka, E., Nishizawa, M., Mori, H., and Ito, S. (1997). Inhibition of nociceptin-induced allodynia in conscious mice by prostaglandin D2. Br. J. Pharmacol. 122:605-610.
222. VanderEnde, D.S. and Morrow, J.D. (2001). Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans after the application of cinnamic aldehyde. J. Am. Acad. Dermatol. 45:62-67.
223. Walch, L., Labat, C., Gascard, J.P., de Montpreville, V., Brink, C., and Norel, X. (1999). Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br. J. Pharmacol. 126:859-866.
224. Cooper, B. (1979). Diminished platelet adenylate cyclase activation by prostaglandin D2 in acute thrombosis. Blood 54:684-693.
225. Eguchi, Y., Eguchi, N., Oda, H., Seiki, K., Kijima, Y., Matsu-ura, Y., et al. (1997). Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc. Natl. Acad. Sci. USA 94:14,689-14,694.
226. Garcia-Fernandez, L.F., Iniguez, M.A., Eguchi, N., Fresno, M., Urade, Y., and Munoz, A. (2000). Dexamethasone induces lipocalin-type prostaglandin D synthase gene expression in mouse neuronal cells. J. Neurochem. 75:460-470.
227. Straus, D.S., Pascual, G., Li, M., Welch, J.S., Ricote, M., Hsiang, C.H., et al. (2000). 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B sig-naling pathway. Proc. Natl. Acad. Sci. USA 97:4844-4849.
228. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., et al. (2000). Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403:103-108.
229. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82.
230. Zhao, L. and Funk, C.D. (2004). Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med. 14:191-95.
231. Spanbroek, R., Grabner, R., Lotzer, K., Hildner, M., Urbach, A., Ruhling, K., et al. (2003). Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 100:1238-1243.
232. Romano, M., Catalano, A., Nutini, M., D'Urbano, E., Crescenzi, C., Claria, J., et al. (2001). 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J. 15:2326-2336.
233. Celletti, F.L., Waugh, J.M., Amabile, P.G., Brendolan, A., Hilfiker, P.R., and Dake, M.D. (2001). Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 7:425-429.
234. Mehrabian, M., Allayee, H., Wong, J., Shi, W., Wang, X.P., Shaposhnik, Z., et al. (2002). Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 91:120-126.
235. Sala, A., Testa, T., and Folco, G. (1996). Leukotriene A4, and not leukotriene B4, is the main 5-lipoxygenase metabolite released by bovine leukocytes. FEBS Lett. 388:94-98.
236. Sala, A., Bolla, M., Zarini, S., Muller-Peddinghaus, R., and Folco, G. (1996). Release of leukotriene A4 versus leukotriene B4 from human polymorphonuclear leukocytes. J. Biol. Chem. 271:17,944-17,948.
237. Maclouf, J., Murphy, R.C., and Henson, P.M. (1989). Transcellular sulfidopeptide leukotriene biosynthetic capacity of vascular cells. Blood 74:703-707.
238. Yokomizo, T., Izumi, T., and Shimizu, T. (2001). Leukotriene B4: metabolism and signal transduction. Arch. Biochem. Biophys. 385:231-241.
239. Friedrich, E.B., Tager, A.M., Liu, E., Pettersson, A., Owman, C., Munn, L., et al. (2003). Mechanisms of leukotriene B4-triggered monocyte adhesion. Arterioscler. Thromb. Vasc. Biol. 23:1761-1767.
240. McIntyre, T.M., Zimmerman, G.A., and Prescott, S.M. (1986). Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc. Natl. Acad. Sci. USA 83:2204-2208.
241. Lehr, H.A., Hubner, C., Finckh, B., Angermuller, S., Nolte, D., Beisiegel, U., et al. (1991). Role of leukotrienes in leukocyte adhesion following systemic administration of oxidatively modified human low density lipoprotein in hamsters. J. Clin. Invest. 88:9-14.
242. Datta, Y.H., Romano, M., Jacobson, B.C., Golan, D.E., Serhan, C.N., and Ewenstein, B.M. (1995). Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation 92:3304-3311.
243. Aiello, R.J., Bourassa, P.A., Lindsey, S., Weng, W., Freeman, A., and Showell, H.J. (2002). Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. 22:443-449.
244. Porreca, E., Conti, P., Feliciani, C., Di Febbo, C., Reale, M., Mincione, G., et al. (1995). Cysteinyl-leukotriene D4 induced IL-1 beta expression and release in rat vascular smooth muscle cells. Atherosclerosis 115:181-189.
245. Devaraj, S. and Jialal, I. (1999). Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler. Thromb. Vasc. Biol. 19:1125-1133.
246. Porreca, E., Di Febbo, C., Di Sciullo, A., Angelucci, D., Nasuti, M., Vitullo, P., et al. (1996). Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb. Haemost. 76:99-104.
247. Nigam, S. and Schewe, T. (2000). Phospholipase A(2)s and lipid peroxidation. Biochim. Biophys. Acta 1488:167-181.
248. Kuwata, H., Yamamoto, S., Takekura, A., Murakami, M., and Kudo, I. (2004). Group IIA secretory phospholipase A2 is a unique 12/15-lipoxygenase- regulated gene in cytokine-stimulated rat fibroblastic 3Y1 cells. Biochim. Biophys. Acta 1686:15-23.
249. Huo, Y., Zhao, L., Hyman, M.C., Shashkin, P., Harry, B.L., Burcin, T., et al. (2004). Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 110:2024-2031.
250. George, J., Afek, A., Shaish, A., Levkovitz, H., Bloom, N., Cyrus, T., et al. (2001). 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104:1646-1650.
251. Kume, N., Cybulsky, M.I., and Gimbrone, M.A. Jr. (1992). Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90:1138-1144.
252. Murohara, T., Kugiyama, K., Ohgushi, M., Sugiyama, S., Ohta, Y., and Yasue, H. (1994). LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am. J. Physiol. 267:H2441-H2449.
253. Chai, Y.C., Howe, P.H., DiCorleto, P.E., and Chisolm, G.M. (1996). Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J. Biol. Chem. 271:17,791-17,797.
254. Lauber, K., Bohn, E., Krober, S.M., Xiao, Y.J., Blumenthal, S.G., Lindemann, R.K., et al. (2003). Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113:717-730.
255. McMurray, H.F., Parthasarathy, S., and Steinberg, D. (1993). Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Invest. 92:1004-1008.
256. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. (1989). Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
257. Steinbrecher, U.P., Parthasarathy, S., Leake, D.S., Witztum, J.L., and Steinberg, D. (1984). Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81:3883-3887.
258. Keaney, J.F. Jr., Xu, A., Cunningham, D., Jackson, T., Frei, B., and Vita, J.A. (1995). Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J. Clin. Invest. 95:2520-2529.
259. Portman, O.W. and Alexander, M. (1969). Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J. Lipid Res. 10:158-165.
260. Liu-Wu, Y., Hurt-Camejo, E., and Wiklund, O. (1998). Lysophosphatidylcholine induces the production of IL-1 beta by human monocytes. Atherosclerosis 137:351-357.
261. Pages, C., Simon, M.F., Valet, P., and Saulnier-Blache, J.S. (2001). Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat. 64:1-10.
262. Xie, Y. and Meier, K.E. (2004). Lysophospholipase D and its role in LPA production. Cell Signal. 16:975-981.
263. Ishii, I., Fukushima, N., Ye, X., and Chun, J. (2004). Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 73:321-354.
264. Fukushima, N., Ishii, I., Contos, J.J., Weiner, J.A., and Chun, J. (2001). Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41:507-534.
265. Anliker, B. and Chun, J. (2004). Cell surface receptors in lysophospholipid signaling. Semin. Cell Dev. Biol. 15:457-465.
266. Guyton, J.R. (2001). Phospholipid hydrolytic enzymes in a 'cesspool' of arterial intimal lipoproteins: a mechanism for atherogenic lipid accumulation. Arterioscler. Thromb. Vasc. Biol. 21:884-886.
267. Tabas, I. (1999). Nonoxidative modifications of lipoproteins in atherogenesis. Annu. Rev. Nutr. 19:123-139.
268. Oorni, K., Pentikainen, M.O., Ala-Korpela, M., and Kovanen, P.T. (2000). Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J. Lipid Res. 41:1703-1714.
269. Khoo, J.C., Miller, E., McLoughlin, P., and Steinberg, D. (1988). Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 8:348-358.
270. Suits, A.G., Chait, A., Aviram, M., and Heinecke, J.W. (1989). Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foamcell formation. Proc. Natl. Acad. Sci. USA 86:2713-2717.
271. Oorni, K., Hakala, J.K., Annila, A., Ala-Korpela, M., and Kovanen, P.T. (1998). Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J. Biol. Chem. 273:29,127-29,134.
272. Kleinman, Y., Krul, E.S., Burnes, M., Aronson, W., Pfleger, B., and Schonfeld, G. (1988). Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J. Lipid Res. 29:729-743.
273. Gorshkova, I.N., Menschikowski, M., and Jaross, W. (1996). Alterations in the physiochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label study. Biochim. Biophys. Acta 1300:103-113.
274. Hurt-Camejo, E., Andersen, S., Standal, R., Rosengren, B., Sartipy, P., Stadberg, E., et al. (1997). Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17:300-309.
275. Camejo, G., Hurt, E., Wiklund, O., Rosengren, B., Lopez, F., and Bondjers, G. (1991). Modifications of low-density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate. Biochim. Biophys. Acta 1096:253-261.
276. Mateu, L., Avila, E.M., Camejo, G., Leon, V., and Liscano, N. (1984). The structural stability of low-density lipoprotein. A kinetic X-ray scattering study of its interaction with arterial proteoglycans. Biochim. Biophys. Acta 795: 525-534.
277. Pentikainen, M.O., Oorni, K., Lassila, R., and Kovanen, P.T. (1997). The proteoglycan decorin links low density lipoproteins with collagen type I. J. Biol. Chem. 272:7633-7638.
278. Han, S.K., Yoon, E.T., and Cho, W. (1998). Bacterial expression and characterization of human secretory class V phospholipase A2. Biochem. J. 331 (Pt. 2):353-357.
279. Riessen, R., Isner, J.M., Blessing, E., Loushin, C., Nikol, S., and Wight, T.N. (1994). Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am. J. Pathol. 144:962-974.
280. Austin, M.A., King, M.C., Vranizan, K.M., Newman, B., and Krauss, R.M. (1988). Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am. J. Hum. Genet. 43:838-846.
281. Schissel, S.L., Tweedie-Hardman, J., Rapp, J.H., Graham, G., Williams, K.J., and Tabas, I. (1996). Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 98:1455-1464.
282. Schissel, S.L., Jiang, X., Tweedie-Hardman, J., Jeong, T., Camejo, E.H., Najib, J., et al. (1998). Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273:2738-2746.
283. Pentikainen, M.O., Lehtonen, E.M., and Kovanen, P.T. (1996). Aggregation and fusion of modified low density lipoprotein. J. Lipid Res. 37:2638-2649.
284. Xu, X.X. and Tabas, I. (1991). Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J. Biol. Chem. 266:24,849-24,858.
285. Dziennis, S., Van Etten, R.A., Pahl, H.L., Morris, D.L., Rothstein, T.L., Blosch, C.M., et al. (1995). The CD11b promoter directs high-level expression of reporter genes in macrophages in transgenic mice. Blood 85:319-329.
286. Gilroy, D.W., Newson, J., Sawmynaden, P., Willoughby, D.A., and Croxtall, J.D. (2004). A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J. 18:489-498.
287. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., and Serhan, C.N. (2001). Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:612-619.
288. Gilroy, D.W., Colville-Nash, P.R., Willis, D., Chivers, J., Paul-Clark, M.J., and Willoughby, D.A. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:698-701.
289. Steed, D.L. (2003). Wound-healing trajectories. Surg. Clin. North Am. 83:547-555, vi-vii.
290. Harwig, S.S., Tan, L., Qu, X.D., Cho, Y., Eisenhauer, P.B., and Lehrer, R.I. (1995). Bactericidal properties of murine intestinal phospholipase A2. J. Clin. Invest. 95:603-610.
291. Buckland, A.G., Heeley, E.L., and Wilton, D.C. (2000). Bacterial cell membrane hydrolysis by secreted phospholipases A(2): a major physiological role of human group IIa sPLA(2) involving both bacterial cell wall penetration and interfacial catalysis. Biochim. Biophys. Acta 1484:195-206.